Two cancer sites, prostate (ICD-9:185.9 and ICD10: C61.9) and rectal cancer (ICD-9: 154.1;ICD-10: C20.9) were selected for the clinical audit.

These specific cancer types were chosen due to their high incidence rate (1), the relevant role of radiotherapy in their treatment, our prior experience, and because all participating institutions treat large numbers of patients for these two cancer types. In the case of rectal cancer, the high incidence and mortality rates associated with this cancer make it an ideal candidate for auditing due to the large impact even small improvements in cancer care could have on clinical outcomes.

Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality
worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer
2014;136(5):E359–86. Doi: 10.1002/ijc.29210.